跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 98,863 条关于
“HR+ HER2- breast cancer”
全部
98,863
临床试验
79,687
药物
2,632
机构
1,175
资讯
15,369
去年
Dalpiciclib Plus Letrozole Shows Promise in Phase II Trial for HR+/HER2- Breast Cancer
去年
Genentech's Inavolisib Receives FDA Approval for Advanced HR+, HER2- Breast Cancer
去年
Researchers Identify Key Resistance Mechanism to CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
10个月前
Biotheryx Completes Enrollment in Phase 1a Trial of First-in-Class CDK4/6 Degrader BTX-9341 for HR+/HER2- Breast Cancer
8天前
FDA Clears IND for Prelude Therapeutics' First-in-Class Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer
去年
Puma Biotechnology Initiates Phase II Trial of Alisertib in HR+/HER2- Breast Cancer
去年
Relay Therapeutics' RLY-2608: A Mutant-Selective PI3Kα Inhibitor Enters Phase I Trials for HR+/HER2- Breast Cancer
4个月前
Avenzo Therapeutics Initiates CDK4/CDK2 Dual Inhibitor Combination Trial for HR+/HER2- Breast Cancer
6个月前
Novartis Acquires Next-Generation PI3Kα Inhibitor SNV4818 in $3 Billion Deal to Strengthen Breast Cancer Pipeline
9个月前
Avenzo's CDK2 Inhibitor AVZO-021 Shows Promising Activity in Breast and Ovarian Cancer Patients
第 1 页,共 1537 页
上一页
下一页